Mill Creek Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Mill Creek Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,535	Closed	-$209K	–	248
2023 Q4	$209K	Sell	1,535 -840	-35%	-$102K	0.01%	227
2023 Q3	$290K	Sell	2,375 -121	-5%	-$15.4K	0.01%	181
2023 Q2	$317K	Hold	2,496	–	–	0.01%	187
2023 Q1	$322K	Hold	2,496	–	–	0.01%	182
2022 Q4	$328K	Buy	+2,496	New	+$323K	0.01%	170

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Mill Creek Capital Advisors's IBB Position: Q1 2024 in Review

Mill Creek Capital Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2024, closing a stake of 1,535 shares — an estimated $209K sold.

Mill Creek Capital Advisors first reported a position in IBB in Q4 2022 and held it in 5 quarters. The position peaked at $328K in Q4 2022. 901 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

Mill Creek Capital Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2024 after selling out during the quarter.
Mill Creek Capital Advisors sold 1,535 iShares Biotechnology ETF shares in Q1 2024, an estimated $209K.
Mill Creek Capital Advisors first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 5 quarters.
Mill Creek Capital Advisors's iShares Biotechnology ETF position peaked at $328K in Q4 2022.
901 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Mill Creek Capital Advisors's 13F filing for Q1 2024, filed 14 May 2024.